Newsletter Tool

To view this email as a web page, click here

Today's Rundown

While Pfizer and Moderna hold the lead, new data from J&J, Novavax show there's 'room for everyone' in the market: analysts
One year of COVID-19: Providence infectious disease expert shares lessons learned from the front lines
Vaccine manufacturing greenhorn Bayer to make 160M doses of CureVac's COVID-19 shot
Lilly drives more access to COVID-19 antibodies with new infusion centers
GSK, Clover part ways on COVID-19 vaccine, putting Dynavax in the spotlight
FAH presses for $32B in provider assistance in next COVID-19 relief package
Summus Global data show huge growth in virtual specialty care amid COVID-19
UPDATED Coronavirus tracker: CDC issues public transit mask mandate

Featured Story

While Pfizer and Moderna hold the lead, new data from J&J, Novavax show there's 'room for everyone' in the market: analysts

By Eric Sagonowsky

With Novavax and Johnson & Johnson data now in hand, the world has efficacy numbers on at least five COVID-19 vaccines. That's plenty for analysts to parse—and they're busy doing not only that, but also sizing up potential sales. The upshot? Blockbuster sales to go around, but some will capture a lot more than others.

One year of COVID-19: Providence infectious disease expert shares lessons learned from the front lines

By Heather Landi

Since COVID-19 arrived a year ago, healthcare workers on the front lines have been waging a war against a pandemic that has killed 429,000 Americans and sickened more than 25 million. What are some lessons learned, what changes will stick, and what have been the hardest moments? Rebecca Bartles, executive director of system infection prevention at Providence, shares her experiences battling the pandemic. Fierce Healthcare also invites you to share your stories one year after COVID-19.

Vaccine manufacturing greenhorn Bayer to make 160M doses of CureVac's COVID-19 shot

By Angus Liu

In its nearly 160-year history, Bayer has never produced vaccines for humans. But the COVID-19 pandemic is changing that. The drugmaker has signed on to help manufacture 160 million doses of German compatriot CureVac’s mRNA coronavirus vaccine next year, counting on its biologics expertise to see it through.

Lilly drives more access to COVID-19 antibodies with new infusion centers

By Beth Snyder Bulik

Eli Lilly's COVID-19 monoclonal antibody isn't getting as much use as it could, thanks to logistical hurdles. So the drugmaker is taking matters into its own hands. The pharma is setting up dedicated local infusion centers across its home state of Indiana, with centers already up and running in the central, northern and southern parts of the state.

GSK, Clover part ways on COVID-19 vaccine, putting Dynavax in the spotlight

By Eric Sagonowsky

First, lackluster data forced GlaxoSmithKline and partner Sanofi back to the drawing board with their COVID-19 shot. Now, the Big Pharma and a biotech partner are parting ways on a separate vaccine collaboration.

FAH presses for $32B in provider assistance in next COVID-19 relief package

By Robert King

The Federation of American Hospitals wants the next COVID-19 relief package to include $32 billion in additional provider assistance and extend a moratorium on Medicare's sequestration payment cuts.

Summus Global data show huge growth in virtual specialty care amid COVID-19

By Brian T. Horowitz

Telehealth has seen a huge boost during the COVID-19 pandemic, but people aren’t just participating in remote visits for fevers and sore throats. They are also seeking out the advice and guidance of specialty providers through virtual sessions. Find out which areas of specialty care saw the largest growth in virtual sessions in 2020.

UPDATED Coronavirus tracker: CDC issues public transit mask mandate

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

COVID-19 Tracker